Abstract: Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.
Type:
Grant
Filed:
September 22, 2009
Date of Patent:
November 27, 2018
Assignee:
RXi Pharmaceuticals Corporation
Inventors:
Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Michelle Miller, Karen G. Bulock
Abstract: Described herein are pharmaceutical compositions including a proton pump inhibitor and an antiparasitic drug. In some embodiments, the compositions can be formulated as a non-solid for oral administration. The compositions can be used to treat gastrointestinal conditions. Methods of treatment using the compositions are also described.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
November 27, 2018
Assignee:
Adamis Pharmaceuticals Corporation
Inventors:
David Clayton Sutherland, James Kyle Zorn, Dennis J. Carlo
Abstract: The invention relates to improved RNAi constructs and uses thereof. The construct has a double stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the sense strand may be modified (e.g., one or both ends of the sense strand is/are modified by four 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2?-O-methyl group at the 2nd 5?-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoids the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
Type:
Grant
Filed:
February 11, 2009
Date of Patent:
November 20, 2018
Assignee:
RXi Pharmaceuticals Corporation
Inventors:
Pamela A. Pavco, Joanne Kamens, Tod M. Woolf, William Salomon, Anastasia Khvorova
Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
Type:
Application
Filed:
February 26, 2018
Publication date:
November 15, 2018
Applicant:
RXi Pharmaceuticals Corporation
Inventors:
Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
Abstract: There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.
Type:
Application
Filed:
December 13, 2017
Publication date:
October 18, 2018
Applicant:
Chase Pharmaceuticals Corporation
Inventors:
Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
Abstract: The present invention relates to methods and compositions for the treatment of alopecia areata. In some aspects, the present invention relates to haptens for use in treating alopecia areata. In other aspects, the present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds the treatment of alopecia areata. In other aspects, the present invention relates to compositions comprising haptens formulated as gels or ointments.
Abstract: A combination of a muscarinic cholinergic receptor agonist with a non-anticholinergic antiemetic agent, and the optional addition of an acetyl choline esterase inhibitor, for the treatment of hypocholinergic disorder of the central nervous system.
Type:
Application
Filed:
September 9, 2016
Publication date:
September 6, 2018
Applicant:
Chase Pharmaceuticals Corporation
Inventors:
Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
Abstract: The present invention provides a method for treating a cancer in a subject involving administering to the subject a compound of formula (II) or (II?): wherein R1, R2, R3, R4, R5, R6 and R7 are independently H, OH, alkoxy or alkylcarbonyloxy, or a pharmaceutically acceptable salt thereof. Also provided is a compound of formula (II) or (II)?, wherein R1 and R2 are independently OH, alkoxy or alkylcarbonyloxy, R3 and R4 are independently H, OH, alkoxy or alkylcarbonyloxy, R6 is H, alkoxy or alkylcarbonyloxy, R5 is H, OH or alkylcarbonyloxy, R6 is H or alkoxy, and R7 is H, or a pharmaceutically acceptable salt thereof.
Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
Type:
Grant
Filed:
March 23, 2011
Date of Patent:
August 7, 2018
Assignee:
RXi Pharmaceuticals Corporation
Inventors:
Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
Abstract: A method for filling a plurality of microdepressions in a major surface of a web with finely divided powder in which the web is fed continuously to and through a powder filling stage including a driven roller. A method of manufacturing an elongate carrier with microdepressions containing finely divided powder comprising steps filling a plurality of microdepressions in a major surface of a web as described, removing from upper surface of the web excess powder not filled within the microdepressions and remaining on areas of the surface between the depressions, and optionally slitting and/or cutting the web in width and/or length.
Abstract: In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective amount of a small molecule that activates NF-?B p65 and increases expression of manganese superoxide dismutase (MnSOD/SOD2) and/or expression of a related protein or enzyme.
Abstract: Aspects of the invention relate to methods for treating ALS comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding superoxide dismutase 1 (SOD1).
Type:
Application
Filed:
July 6, 2016
Publication date:
July 12, 2018
Applicant:
RXi Pharmaceuticals Corporation
Inventors:
James Cardia, Michael Byrne, Karen G. Bulock, Pamela A. Pavco, Lyn Libertine
Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
Type:
Application
Filed:
June 30, 2017
Publication date:
June 7, 2018
Applicant:
RXi Pharmaceuticals Corporation
Inventors:
Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
Abstract: Dry powder inhaler dose counters capable of making a display move swiftly between digits, in contrast to the progressive movement that occurs in simple gearing mechanisms.
Type:
Grant
Filed:
August 3, 2015
Date of Patent:
June 5, 2018
Assignee:
Adamis Pharmaceuticals Corporation
Inventors:
Bryan E. Rolfs, Benjamin L. Rush, Jonathan D. Toback, Peter D. Hodson, Stephan W. Stein, Michael K. Domroese
Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
Type:
Grant
Filed:
July 10, 2015
Date of Patent:
May 29, 2018
Assignee:
MEDICIS PHARMACEUTICAL CORPORATION
Inventors:
Michael T. Nordsiek, Jefferson J. Gregory
Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making betalactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
Type:
Grant
Filed:
April 14, 2016
Date of Patent:
May 8, 2018
Assignee:
RXi Pharmaceuticals Corporation
Inventors:
Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
Abstract: A pharmaceutical combination of memantine and a non-anticholinergic antiemetic agent for the treatment of hypocholinergic disorders in further combination with high doses of donepezil and with solifenacin, and kits comprising said combination. A pharmaceutical combination of memantine and solifenacin for the treatment of hypocholinergic disorders, including Alzheimer type dementia, in further combination with high doses of donepezil, and kits comprising said combination.
Type:
Application
Filed:
October 27, 2017
Publication date:
May 3, 2018
Applicant:
CHASE PHARMACEUTICALS CORPORATION
Inventors:
Kathleen E. CLARENCE-SMITH, Thomas N. CHASE